Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

FDA approval covers ER-positive/HER2-negative metastatic disease with ESR1 mutations after ≥1 endocrine line, with ...

Preclinical studies by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, showed how a new combination therapy for hormone-resistant, ...

“This triple therapy approach could be a game-changer for patients whose (breast) cancers no longer respond to standard hormone treatments,” said Rumela Chakrabarti, Ph.D., the study’s senior author ...

This approach may overcome endocrine resistance, a key challenge in advanced breast cancer treatment. Analysts note the early FDA approval, ahead of its PDUFA date, signals regulatory confidence and ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With ...

Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...